Nanobiotix S.A. (NBTX) is a Paris-based, late-clinical-stage biotechnology company developing physics-based nanotherapeutics, led by its radioenhancer JNJ-1900 (NBTXR3), which is partnered with Johnson & Johnson and under study in head and neck, lung, and melanoma indications. In midday U.S. trading the Nasdaq-listed shares traded at $27.92, up 3.79% from the previous session's close of $26.90, a gain of $1.02. The direction is unambiguously higher, but no verified catalyst has been identified: the move follows a five-session, 18.4% decline and looks like a stabilization in a highly volatile small-cap biotech rather than a response to new information.
No verified news or fundamental catalyst found. A review of company releases, regulatory filings, analyst actions, and clinical disclosures turned up nothing published on or before today's move that would justify a re-rating of a company with a market capitalization of roughly $1.4 billion. The most recent corporate items were routine: a November 9 notice of participation in the Jefferies and UBS healthcare conferences in London on November 16–17, and a November 12 monthly disclosure of shares and voting rights totaling 50.97 million shares outstanding. Neither carries valuation weight.
The more plausible explanation is technical. The stock had fallen in five straight sessions from $32.95 to $26.90, an 18.4% drawdown, and had given back most of an October rebound that had taken it from $21.08 to $34.53. A bounce after such a run is consistent with short-covering and dip buying rather than fresh fundamental conviction. The company's own trading history supports that reading: the shares have averaged an absolute daily move of about 4.1% over the past 60 sessions, with 26 of those sessions producing a swing of 3.8% or more. Today's gain is smaller than the stock's own typical range.
The rebound was not a U.S.-only event. The Euronext Paris line rose more than 5% during European hours, well ahead of the Nasdaq gain, which typically points to a home-market-led move that the American depositary receipts then track with a lag. Turnover was unremarkable — a sign that buyers met thin supply rather than that institutions were accumulating. Average daily volume runs near 150,000 shares, a light float for a $1.4 billion valuation.
Technically, the advance is a bounce inside a downtrend. The shares remain below their 20-day average near $30.70 and below the $33 zone where the November rally stalled, while the October low around $21 stands as the nearest major support. The broader tape offered no obvious sector-wide trigger, and the move is best read as company-specific volatility rather than a biotech-wide rotation.
A score of 0 on this scale means no meaningful news and a price move that is normal for the stock; 100 means transformative news and an extreme, rare move. Nanobiotix scores 6 out of 100.
The news component is essentially empty: no verified release, filing, or analyst action preceded the gain, and the only recent disclosures were routine conference scheduling and a monthly share-count update, both immaterial relative to a company of this size. The price component is equally muted. At 3.79%, today's move was slightly smaller than the stock's typical daily swing of about 4.1%, and swings of similar or larger size occurred 26 times in the last 60 sessions. With weak news and unexceptional price behavior, the two factors combine into a very low score.
Attention now turns to the cadence of JNJ-1900 (NBTXR3) disclosures. The Phase 3 head and neck cancer study transferred to Johnson & Johnson's sponsorship remains the pivotal asset, and further data from investigator-led programs in non-small cell lung cancer and anti-PD-1-resistant melanoma are the events most capable of moving the stock. The company has guided to additional cohort data from its MD Anderson collaborations, with the timing set by trial enrollment rather than by the company.
Financially, Nanobiotix reported cash and equivalents of €110.9 million at June 30, which management says funds operations into 2029 — a runway that limits near-term dilution risk but does not remove it if development costs rise. Full-year 2026 results and the next cash update will be the key checkpoints. Analyst sentiment remains constructive, with a consensus rating in the buy range and targets spread widely from $30 to $64, a dispersion that itself signals how much uncertainty surrounds the program's timing. Investors should expect continued double-digit percentage swings in either direction.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only those posting the best results right now are surfaced in this section. Bots differ meaningfully by strategy logic, holding period, performance metrics, and the symbols they trade, so the lineup rotates as market conditions shift. Reviewing the current leaders is a practical way to see which approaches are working — and a sensible starting point for building your own watchlist.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 24 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In 78 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
NBTX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for NBTX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 151 of 188 cases where NBTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-46.722) is normal, around the industry mean (3.592). P/E Ratio (-28.101) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology